# Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech

*Источник: Fierce Biotech*
*Дата: 2026-09-15*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5" target="_blank">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>

[Оригинал](https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic)